We first analyzed breast cancer cohorts in “The Cancer Genome Atlas” (TCGA), Oncomine, and found that high PF4 levels correlated with increased survival of breast cancer patients (Figure 6A, left panel); and that decreased PF4 levels are observed in stage III/IV compared with stage I/II in breast cancer progression (Figure 6A, right panel). Here, PF4 is linked to breast carcinoma.